{
  "id": 882514,
  "title": "MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta",
  "url": "https://urgent.news/2026/08/14/maplight-presses-the-pause-button-adc-therapeutics-considers-what-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T14:10:55.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/maplight-presses-the-pause-button-adc-therapeutics-considers-what-to-do-with-zynlonta/"
  },
  "original_language": "en",
  "account": null,
  "summary": "⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s disease psychosis. MapLight also ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}